

## anti-inflammatoty and immuno-therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Immunosuppressants drugs	3 studies <sup>1</sup>	1.11 [0.59 ; 2.09], 1 RCT, I2=0% inconclusive result	1.06 [0.80 ; 1.41], 1 RCT, I2=0% inconclusive result	0.87 [0.78 ; 0.99], 3 RCTs, I2=0% demonstrated moderate degree of certainty	-
Immunostimulants drugs	2 studies <sup>2</sup>	-	-	2.00 [0.16 ; 24.66], 1 RCT, I2=0% inconclusive result	-
leflunomide	1 study <sup>3</sup>	-	-	-	-

### Notes

<sup>1</sup>RECOVERY, 2022 (NCT04381936) ; BACC Bay Tocilizumab Trial, 2020 (NCT04356937) ; TOCOVID, 0 (NCT04332094)

<sup>2</sup>LIFESAVER, 2021 (NCT04374526) ; Cai -FAVIPRAVIR, 2020 (ChiCTR2000029600)

<sup>3</sup>Wang, 2020 (ChiCTR2000030058)